Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S233500, C514S457000
Reexamination Certificate
active
07148252
ABSTRACT:
This invention relates to methods for using benzopyranones, or their pharmaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis. The benzopyranones have the formula:wherein R1, R2, R3, n and p are as defined herein.
REFERENCES:
patent: 6291456 (2001-09-01), Stein et al.
patent: 6331562 (2001-12-01), Bhagwat et al.
patent: 6372739 (2002-04-01), Stein et al.
Al-Saffar et al., 1996, “Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants”, Am J Clin Pathol. 105(5):628-39.
Alonzi et al., 1998, “Interleukin 6 is required for the development of collagen-induced arthritis”, J Exp Med. 187(4):461-8.
Barkhem et al., 1998, “Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists”, Mol Pharmacol. 54(1):105-12.
Blsmar et al., 1995, “Increased cytokine secretion by human bone marrow cells after memopause or discontinuation of estrogen replacement”, J Clin Endocrinol Metab. 80(11):3351-5.
Bodine et al., 1998, “Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression”, Endocrinology. 139(4):2048-57.
Brandenberger et al., 1998, “Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues”, J Clin Endocrinol Metab. 83(3):1025-8.
Chen et al., 2001, “Molecular basis for the constitutive activity of estrogen-related receptor alpha-1”, J Biol Chem. 276(30):28465-70.
Chung et al., 2002, “Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2
eu and cell membrane estrogen receptor in breast cancer”, Int J Cancer. 97(3):306-12.
Clinton and Hua, 1997, “Estrogen action in human ovarian cancer”, Crit Rev Oncol Hematol. 25(1):1-9.
Cooke et al., 1998, “Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse”, Biol Reprod. 59(3):470-5.
Couse et al., 1997, “Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse”, Endocrinology. 138(11):4613-21.
Coward et al., 2001, “4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma”, Proc Natl Acad Sci U S A. 98(15):8880-4.
Das et al., 1997, “Estrogenic responses In estrogen receptor-α deficient mice reveal a distict estrogen signaling pathway”, Proc. Natl. Acad. Sci. USA 94:12786-91.
Devlin et al., 1998, “IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures”, J Bone Miner Res. Mar. 1998;13(3):393-9.
Duan et al., 1998, “Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation”, Endocrinology. 139(4):1981-90.
Enmark et al., 1997, “Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern”, J. Clin Endocrinol Metab. 82(12):4258-65.
Eustace et al., 1993, “Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro”, Gynecol Oncol. 50(1):15-19.
Farhat et al., 1996, “The vascular protective effects of estrogen”, FASEB J. 10(5):615-24.
Garrett et al., 1997, “A murine model of human myeloma bone disease”, Bone 20(6):515-20.
Girasole et al., 1992, “17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens”, J Clin Invest. 89(3):883-91.
Grese et al., 1997, “Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene”, J Med Chem. 40(2):146-67.
Gupta et al., 1985, “7-hydroxy-4-phenyl-3(4-hydroxyphenyl)-coumarin—a new interceptive agent”, Indian J Exp Biol. 23(11):638-40.
Gustafsson et al., 1998, “Therapeutic potential of selective estrogen receptor modulators”, Curr Opin Biol. 2(4):508-11.
Hata et al., 1998, “Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells”, Oncology. 55 Suppl 1:35-44.
Hughes et al., 1996, “Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta”, Nat Med. 2(10):1132-6.
Iafrati et al., 1997, “Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice”, Nat Med. 3(5):545-8.
Jansson et al., 1994, “Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice”, J Neuroimmunol. 53(2):203-7.
Jeltsch et al., 1987, “Structure of the human oestrogen-responsive gene pS2”, Nucleic Acids Res. 15(4):1401-14.
Jilka et al, 1995, “Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6”, Exp Hematol. 23(6):500-6.
Jilka et al., 1992, “Increased osteoclast development after estrogen loss: mediation by interleukin-6”, Science 57(5066):88-91.
Kelly et al., 1999, “Estrogen Modulation of G-protein-coupled Receptors”, Trends Endocrinol Metab. 10(9):369-374.
Kimble et al., 1996, “Estrogen deficiency increases the ability of stromal cell to support murine osteoclastogenesis via an interleukin-1and tumor necrosisfactor-mediatedstimulation of macrophage colony-stimulating factor production”, J Biol Chem. 271(46):28890-7.
Kimble et al., 1995, “Simultaneous block of interkeukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period”, Endocrinology. 136(7):3054-61.
Klein et al., 1991, “Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia”, Blood. 78(5):1198-204.
Klein et al., 1989, “Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by Interleukin-6”, Blood. 73(2):517-26.
Koo et al., 1992, “Interkeukin-6 and renal cell cancer: production, regulation, and growth effects”, Cancer Immunol Immunother. 35(2):97-105.
Korach et al., 1994, “Insights from the study of animals lacking functional estrogen receptor”, Science 266(5190):1524-7.
Krege et al., 1998, “Generation and reproductive phenotypes of mice lacking estrogen receptor beta”, Proc Natl Acad Sci U S A.95(26):15677-82.
Kuiper et al., 1997, “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta”, Endocrinology. Mar. 1997;138(3):863-70.
Kurihara et al., 1989, “Generation of osteoclasts from isolated hematopoietic progenitor cells”, Blood 74(4):1295-302.
Laflamme et al., 1998, “Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout that rat brain: anatomical evidence of distinct roles of each subtype”, J Neurobiol. 36(3):357-78.
Lednicer et al., 1965, “Mammalian Antifertility Agents: Basic Ethers of 3,4—Diphenylcoumarin”, J. Med. Chem. 8:725-726.
Leisten Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin. Clin Immunol Immunopathol. Jul. 1990;56(1):108-15.
Levin et al., 1999, “Cellular Functions of the Plasma Membrane Estrogen Receptor”, Trends Endocrinol Metab. 10(9):374-377.
Lorenzo et al., 1987, “Colony-stimulating factors regulate the developmen
Delacroix-Muirheid C.
Jones Day
Low Christopher S. F.
Signal Pharmaceuticals LLC
LandOfFree
Use of benzopyranones for treating or preventing a primary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of benzopyranones for treating or preventing a primary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of benzopyranones for treating or preventing a primary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719629